Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes

類似資料

• Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
  著者:: Fala, Loretta
  出版事項: (2015)
• The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
  著者:: Steven, Sebastian, 等
  出版事項: (2017)
• The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
  著者:: McGill, Janet B.
  出版事項: (2014)
• Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)
  著者:: Latif, Azka, 等
  出版事項: (2020)
• Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
  著者:: Verma, Subodh, 等
  出版事項: (2018)